RT @Nymne: Ni vet att det ser väldigt bra ut för Oxford-AstraZeneca? https://t.co/j585lW8zXH
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/b2oRLyriEo
RT @Nymne: Ni vet att det ser väldigt bra ut för Oxford-AstraZeneca? https://t.co/j585lW8zXH
@TriciaMcGuigan2 @davidplans @FatEmperor Hi there. Just gonna leave this here for you: https://t.co/3aLdCxd4nW
RT @ProfKatieEwer: Our latest data from @JennerInstitute and @OxfordVacGroup in showing that the Oxford/AZ #COVID19 #vaccine is safe and im…
RT @LancetRH_Europe: The #Oxford vaccine ChAdOx1 nCoV-19 appears to be better tolerated in #older adults than in #younger adults and has si…
RT @mukeshkapila: The #Oxford #COVID19 vaccine group are to be commended for publishing their results in peer-reviewed medical journals an…
@Ascensione_xxy9 @Raffaella017 @atimo13 In fase 3 hanno studiato SOLO la risposta del sistema immunitario dopo due dosi. Che prevenga i contagi lo può sapere SOLO in fase 4, cioè quando vaccina una percentuale crescente di popolazione. E può anche fallire
RT @gorka_orive: VACUNA OXFORD Resultados del ensayo clínico fase II de la vacuna ChAdOx1 nCoV-19 de Oxford/AstraZeneca. Buen perfil de seg…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
The ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, shows to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age. Older adults hv higher risk from COVID-19 & should be the
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
Seguridad e inmunologia de la vacuna: fase 2/3, mejor a informarse bien: https://t.co/EIV5RFnLVd
@ruggledome Hard to say w/out knowing which vaccine they are referring to. Adverse events like fever and mild flu symptoms seem to be most common. Here are links on Pfizer, Moderna & Oxford vax https://t.co/s3MyTMiJBN https://t.co/H7krwilpeU https://
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial - The Lancet https://t.co/6VS3nbfL5b
RT @gorka_orive: VACUNA OXFORD Resultados del ensayo clínico fase II de la vacuna ChAdOx1 nCoV-19 de Oxford/AstraZeneca. Buen perfil de seg…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @LupitaJuarezH: Vacuna de #Oxford y #AstraZeneca genera respuesta inmune en todas las edades, de acuerdo con los resultados del ensayo c…
RT @Sofiavi60344861: Por fin empiezan los datos serios
RT @EricTopol: Something very positive, not to be taken for granted: the vaccines are working well in people > 65 years old New data from @…
RT @TheLancet: Authors note that their new findings could be encouraging if the immune responses found in their study are associated with p…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @DarkLadyMouse: @Alberto_Varese @danielagatelli1 Sì però i risultati della fase 2 di quello di AstraZeneca che è in dirittura d'arrivo s…
@Alberto_Varese @danielagatelli1 Sì però i risultati della fase 2 di quello di AstraZeneca che è in dirittura d'arrivo sono pubblicati su The Lancet. E non mi sembra che in quel caso nessuno ponga problemi di eccessiva velocità nella sperimentazione come h
RT @gorka_orive: VACUNA OXFORD Resultados del ensayo clínico fase II de la vacuna ChAdOx1 nCoV-19 de Oxford/AstraZeneca. Buen perfil de seg…
RT @SharkawyMD: This is the first data reporting an excellent safety profile AND immune response in older subjects for a #Covid19 vaccine.…
La vacuna contra SARS CoV2 caussnte de COVID, de UK, muedtra resultados de seguridad y tolerancia tanto en pacientes de 18 a 55 años como mayores de 56 años, con reactividad reducida (efectos adversos que suceden al aplicar una vacuna como fiebre, cuerpo c
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @HashemGhaili: Updates on Oxford COVID-19 Vaccine. Research Paper: https://t.co/T5kgGwqoEc Learn more: https://t.co/6PdSVk83P2 #Coron…
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial - The Lancet https://t.co/V2hozN7id3
RT @DamarisIntriago: Pfizer, Moderna y Sputnik V: Nota de prensa. Oxford/AstraZeneca: Paper en The Lancet. Por eso soy fan de la candid…
RT @BogochIsaac: We are likely to hear results from the Phase 3 AstraZeneca (Oxford) vaccine trial imminently. But buried in the news are…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @alejandroorrico: PAPER IMPORTANTE‼️ Fase II/III #vacuna #Oxford: 560 participantes (18-55; 56-70; >70) Bien tolerada ✅ y segura ✅…
RT @ajpollard1: Encouraging results showing the same immune response in our study of ChAdOx1 nCoV-19 in older adults as in younger adults h…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @GlasgowCRF: Results from the @OxfordVacGroup phase 2 study in older adults - Strong immune response in older adults, & well tolerated. 👇
RT @OSI_Updates: Encouraging news to wake up to this morning. Phase III trials of the Oxford vaccine are ongoing, with early efficacy readi…
RT @gorka_orive: VACUNA OXFORD Resultados del ensayo clínico fase II de la vacuna ChAdOx1 nCoV-19 de Oxford/AstraZeneca. Buen perfil de seg…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
Zur Abwechslung auch mal was Positives.
RT @drphilhammond: Well done the Oxford/AstraZeneca team for releasing their vaccine results through a peer reviewed journal, rather than a…
RT @BogochIsaac: We are likely to hear results from the Phase 3 AstraZeneca (Oxford) vaccine trial imminently. But buried in the news are…
RT @Saber_IMSS: Conoce los resultados del nivel de seguridad e inmunogenicidad de la vacuna contra #COVID19 reportado en @TheLancet por la…
RT @HashemGhaili: Updates on Oxford COVID-19 Vaccine. Research Paper: https://t.co/T5kgGwqoEc Learn more: https://t.co/6PdSVk83P2 #Coron…
@TheLancet publicó ayer los resultados de fase II de la vacuna contra el SARS-CoV-2 que desarrollan la Universidad de Oxford y AstraZeneca. Probando seguridad y efectividad en todos los grupos de edad analizados, incluyendo los adultos mayores de 70 años
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/gDmB7HwbUf
RT @acinnacional: Siguen las buenas noticias sobre las vacunas para la #COVIDー19; hoy se publicó en @TheLancet https://t.co/pngxGdGKOL, lo…
RT @virgilioh: 🔸️ Se excluye a la población considerada como frágil, pero, da mucho gusto ver que aparentemente la vacuna ChAdOx1 nCoV-19 e…
RT @alishehri1400: #الأخبار_الحلوة #فيروس_كورونا #صوت_الطبيب 🔵نتائج مبشرة ل #لقاح_كوفيد١٩ من (جامعة أكسفورد وأسترازنكا) *يمكن تحمله بشكل أف…
RT @acinnacional: Siguen las buenas noticias sobre las vacunas para la #COVIDー19; hoy se publicó en @TheLancet https://t.co/pngxGdGKOL, lo…
RT @gorka_orive: Resultados del ensayo clínico fase II de la candidata a vacuna ChAdOx1 nCoV-19 de Oxford/AstraZeneca. Buen perfil de segur…
RT @gorka_orive: VACUNA OXFORD Resultados del ensayo clínico fase II de la vacuna ChAdOx1 nCoV-19 de Oxford/AstraZeneca. Buen perfil de seg…
RT @ajpollard1: Encouraging results showing the same immune response in our study of ChAdOx1 nCoV-19 in older adults as in younger adults h…
RT @EricTopol: Something very positive, not to be taken for granted: the vaccines are working well in people > 65 years old New data from @…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
It being labelled as ChAdOx1 would suggest that it is the vaccine https://t.co/MfBTHadjsU
Read more in #TheLancet https://t.co/B3XK6JwxCe News Source: #BBC https://t.co/Sn6618fwum? #coronavirus #covid19 #virus #pandemic #lung #SARS #pneumonia #SARSCoV2 #genome ##coronavirus #covid19 #virus #pandemic #lung #SARS #pneumonia #SARSCoV2 #genome h
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @gorka_orive: VACUNA OXFORD Resultados del ensayo clínico fase II de la vacuna ChAdOx1 nCoV-19 de Oxford/AstraZeneca. Buen perfil de seg…
RT @ajpollard1: Encouraging results showing the same immune response in our study of ChAdOx1 nCoV-19 in older adults as in younger adults h…
RT @acinnacional: Siguen las buenas noticias sobre las vacunas para la #COVIDー19; hoy se publicó en @TheLancet https://t.co/pngxGdGKOL, lo…
RT @Gansrob: Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/44UZB1JchJ
RT @ajpollard1: Encouraging results showing the same immune response in our study of ChAdOx1 nCoV-19 in older adults as in younger adults h…
#الأخبار_الحلوة #فيروس_كورونا #صوت_الطبيب 🔵نتائج مبشرة ل #لقاح_كوفيد١٩ من (جامعة أكسفورد وأسترازنكا) *يمكن تحمله بشكل أفضل لدى كبار السن منه لدى البالغين الأصغر سنًا. *يعطي مناعة مماثلة في جميع الفئات العمرية بعد الجرعة التعزيزية. https://t.co/S2EqzFtjET
Phase 2 trial of Oxford COVID-19 vaccine finds it is safe and provokes immune response in young as well as in older adults – via @TheLancet https://t.co/UpwIV3xD92 Commentary: https://t.co/nuRPcfLbKf
RT @Vin_Diwakar: Delighted to see 2 paediatricians & old colleagues @ajpollard1 @SaulFaust at the forefront of COVID 19 vaccine research &…
Delighted to see 2 paediatricians & old colleagues @ajpollard1 @SaulFaust at the forefront of COVID 19 vaccine research & publishing promising results #respect Expressions of interest for vaccinators https://t.co/OIdoclmoR5 @RCPCHtweets @NHSEngland
Updates on Oxford COVID-19 Vaccine. Research Paper: https://t.co/rcK6YvjUdj Learn more: https://t.co/Ag3jsbI8Dc #Coronavirus #COVID_19 #COVID_2019 #CoronavirusUpdates #Oxford #Vaccine https://t.co/ZQJsDuRCdK
The AstraZeneca/Jenner Phase 2 Study published @TheLancet ChAdOx1 nCoV-19 vaccine was safe and well tolerated with a lower reactogenicity profile in older adults than in younger adults. https://t.co/FgP4OhzI1X
RT @JennerInstitute: The Oxford-AstraZeneca #COVID19 #vaccine is safe and immunogenic across age groups https://t.co/0sf2GSdHTC
RT @TheLancet: NEW—UK’s #COVID19 vaccine shows similar safety and immunogenicity results in healthy older adults (aged 56 years & over) to…
RT @PabloFuente: #COVID19 Los datos, que se conocieron en parte el mes pasado, y que ahora son ahora publicados en su totalidad en The Lanc…
@KurtadikarKetan @RNAiAnalyst No, it's not in their protocol for this https://t.co/T7aIZMahWo
The Lancet: AstraZeneca's COVID-19 vaccine demonstrated a strong immune response in elderly patients, according to the Phase 2/3 trial. (ENG) https://t.co/wbI4N8r4nQ
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/zlWKESE7bo
RT @ncholiA: Adenovirüs vektörlü ChAdOx1 nCoV-19 adlı @OxfordVacGroup/@AstraZeneca aşısının FazII/III klinik çalışmasında umut edilen bağış…
🔸️ Se excluye a la población considerada como frágil, pero, da mucho gusto ver que aparentemente la vacuna ChAdOx1 nCoV-19 es bien tolerada y con inmunogenicidad similar en jóvenes y personas >70 años https://t.co/zb54YSsWZ2
Excelente noticia!!
RT @gorka_orive: VACUNA OXFORD Resultados del ensayo clínico fase II de la vacuna ChAdOx1 nCoV-19 de Oxford/AstraZeneca. Buen perfil de seg…
RT @richardhorton1: The phase II results of the Oxford/AstraZeneca vaccine are here. Extremely encouraging news. It’s hard to believe we ha…
RT @mtmdphd: Safety & immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young & old adults (COV002): Phase…
Safety & immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young & old adults (COV002): Phase 2/3 RCT [Nov 18, 2020] Ramasamy et al. @TheLancet https://t.co/k71fRiVrSs #NCT04400838 #2019nCoV #COVID19 #CCC19 Impt for
RT @JeanneBartram: Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV0…